Marc Moreau, MD
Cardiovascular Disease · Amarillo, TXNPI 1487628293
Payments from drug & device makers
Across 333 payments — averaging $37.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Medtronic$2K
- Abiomed$1K
- Penumbra, Inc.$1K
- Amgen$991
- Abbott$546
- plus $4K from 27 others
What the payments were for
- Travel & lodging$2,95524%
- Food & beverage$7,36460%
- Education$1721%
- Other$1,88015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $1,947 |
| Medtronic(2 entities) | 19 | $1,944 |
| Abiomed | 14 | $1,485 |
| Penumbra, Inc. | 2 | $1,106 |
| Amgen | 66 | $991 |
| Abbott | 17 | $546 |
| Novartis | 30 | $539 |
| AstraZeneca | 18 | $512 |
| Merck | 27 | $446 |
| E.r. Squibb & Sons, L.L.C. | 44 | $420 |
| Boston Scientific | 3 | $338 |
| Shockwave Medical, Inc | 2 | $295 |
| Pfizer | 14 | $239 |
| Boehringer Ingelheim | 10 | $191 |
| Biotronik Inc. | 2 | $183 |
| Teleflex LLC | 1 | $150 |
| Eisai Inc. | 14 | $131 |
| Johnson & Johnson | 7 | $118 |
| Amarin Pharma, Inc. | 7 | $117 |
| Bayer | 6 | $116 |
| Philips North America LLC | 1 | $106 |
| Lexicon Pharmaceuticals, Inc. | 4 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $75 |
| Novo Nordisk | 3 | $56 |
| Actelion Pharmaceuticals US, Inc. | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $45 |
| Cardinal Health 200 LLC | 2 | $34 |
| Acist Medical Systems, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Gilead | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$1,880
- TurboHawk$1,324
- RUBY Coil$1,106
- Impella$1,029
- SYMPLICITY G3$180
- Vascular Lithotripsy$153
- Catheter - GuideLiner$150
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$142
- General - Balloon Catheters$132
- FARXIGA$125
- GENERAL VASCULAR INTERVENTION$124
- COROFLOW$113
- VYNDAQEL$110
- Lasers$106
- Orsiro Mission$104
How this compares
$12,371 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $379,771 |
| EntrestoSacubitril/Valsartan | 203 | $220,102 |
| XareltoRivaroxaban | 203 | $195,264 |
| Repatha SureclickEvolocumab | 229 | $159,847 |
| VerquvoVericiguat | 105 | $115,507 |
| FarxigaDapagliflozin Propanediol | 65 | $47,844 |
| Praluent PenAlirocumab | 62 | $28,811 |
| MultaqDronedarone Hcl | 14 | $24,735 |
| BrilintaTicagrelor | 29 | $20,153 |
| Repatha SyringeEvolocumab | 34 | $19,690 |
| JardianceEmpagliflozin | 18 | $16,902 |
| ClopidogrelClopidogrel Bisulfate | 1,197 | $13,904 |
| Losartan Potassium | 691 | $8,177 |
| Doxazosin Mesylate | 339 | $8,006 |
| Verapamil Hcl | 494 | $6,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $239 | $379,771373 claims |
| NovartisEntresto | $539 | $220,102203 claims |
| Johnson & JohnsonXarelto | $118 | $195,264203 claims |
| MerckVerquvo | $446 | $115,507105 claims |
| AstraZenecaFarxiga, Brilinta | $512 | $67,99794 claims |
| Sanofi-aventis U.S. LLCMultaq | $18 | $24,73514 claims |
| Boehringer IngelheimJardiance | $191 | $16,90218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Amarillo
- David BrabhamAmarillo$11.5M
- Alfred ChuAmarillo$1.3M
- Joaquin Martinez Arraras CaroAmarillo$1.2M
- Rajesh NambiarAmarillo$574K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.